NCT00833716

Effect of Renal Impairment on the Pharmacokinetics of NN9535

An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NN9535 in Subjects With Normal Renal Function and Various Degrees of Impaired Renal Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535.

Conditions

• Diabetes
• Diabetes Mellitus, Type 2
• Renal Impairment

Interventions

Type	Name	Description
DRUG	semaglutide	10 mg/mL of semaglutide solution for s.c. injection, single dose

Timeline

• Start date: 2009-02-02
• Primary completion: 2010-07-26
• Completion: 2010-07-26
• First posted: 2009-02-02
• Last updated: 2017-04-04

Locations

3 sites across 1 country: United States